India’s Obesity Drug Boom is brought to you by

ALKEM

💊

Alkem Laboratories

has stepped into India’s booming GLP-1 space with the launch of Semaglutide at just ₹450 per week, making advanced diabetes and weight-loss treatment far more accessible. With DCGI approval in place, the company is also introducing a reusable injection pen to reduce long-term costs and improve patient adherence, a smart move in a price-sensitive market. CEO Vikas Gupta highlighted that the goal is to expand access to cutting-edge therapies through affordable pricing and strong distribution, bringing more patients into the treatment ecosystem. As more Indian players enter this space, expect a sharp price correction and massive growth in the weight-loss drug market.